Determination of natriuretic peptides in emergency: Does it provide useful prognostic information?;Determinación de péptidos natriuréticos en urgencias: ¿aportan información pronóstica útil?

Emergencias

Volumn 23, Issue 6, 2011, Pages 428-429

  Anguita Sánchez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84055188656     PISSN: 11376821     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (21)

1. Anguita Sánchez M, Crespo Leiro MG, de Teresa Galván E, Jiménez Navarro M, Alonso-Pulpón L, Muñiz García J; PRICE Study Investigators. Prevalence of heart failure in the Spanish general population aged over 45 years. The PRICE Study. Rev Esp Cardiol. 2008;61:1041-9.
2. Zamora E, Lupón J. Heart failure units in Spain: state of the art. Rev Esp Cardiol. 2007;60:874-7.
3. Llorens P, Martín-Sánchez FJ, González-Armengol JJ, Herrero P, Jacob J, Álvarez AB, et al. Perfil clínico de los pacientes con insuficiencia cardíaca aguda en los servicios de urgencias. Datos preliminares del Estudio EAHFE (Epidemiology Acute Heart Failure Emergency). Emergencias. 2008;20:154-63.
4. Llorens P. Implicación de las nuevas guías de la Sociedad Europea de Cardiología en el tratamiento de la insuficiencia cardiaca aguda: ¿debemos cambiar nuestros esquemas en urgencias? Emergencias. 2009;21:143-7.
5. Mebazaa E, Pang PS, Tavares M, Collins SP, Storrow S, Laribi S, et al. The impact of early standard therapy on dypsnoea in patients with acute heart failure: the URGENT dypsnoea study. Eur Heart J. 2010;31:832-41.
6. Anguita M, Montes P, Jordán A, Casares G, Gómez I, Recio J, et al. Utility of NT-proBNP for diagnosing heart failure in a heterogeneous population of patients with dyspnea. Spanish multicenter study. Rev Esp Cardiol. 2006;59:465-72.
7. Murray H, Cload B, Collier CP, Sivilotti LA. Potential impact of N-terminal pro-BNP testing on the emergency department evaluation of acute dypsnea. Can J Emerg Med. 2006;8:251-8.
8. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordóñez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330-7.
9. Januzzi JL Jr, Sakhuja R, O'donoghue M, Baggish AL, Anwaruddin S, Chae CU, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166:315-20.
10. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647-54.
11. Rutten JH, Steyerberg EW, Boomsma F, van Saase JL, Deckers JW, Hoogsteden HC, et al. N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome. Am Heart J. 2008;156:71-7.
12. Moe GW, Howlett J, Januzzi JL, Zowall H; Canadian Multicenter Improved Management of Patients With Congestive Heart Failure (IMPROVE-CHF) Study Investigators. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation. 2007;115:3103-10.
13. Schneider HG, Lam L, Lokuge A, Krum H, Naughton MT, De Villiers Smit P, et al. B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann Intern Med. 2009;150:365-71.
14. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-30.
15. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49:1733-9.
16. Anguita M, Esteban F, Castillo JC, Mazuelos F, López-Granados A, Arizón JM, et al. Utilidad de los valores del péptido natriurético cerebral frente al control clínico habitual para la monitorización del tratamiento en pacientes con insuficiencia cardiaca. Med Clin (Barc). 2010;135:435-40.
17. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al, for the TIMI-CHF investigators. BNP-guided vs symptom-guided heart failure therapy. The TIME-CHF trial. JAMA. 2009;301:383-92.
18. Parapakkham P, Parapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy. A metaanalysis. Arch Intern Med. 2010;170:507-14.
19. Miró O, Jacob J, Martín-Sánchez FJ, Herrero P, Pavón J, Pérez-Durá MJ, et al. Implicaciones pronósticas de la posibilidad de determinar con carácter urgente el péptido natriurético tipo B en el servicio de urgencias en pacientes con insuficiencia cardiaca aguda: estudio PICASU-2. Emergencias 2011;23:437-46.
20. Bayes-Genis A, Pascual-Figal D, Fabregat J, Domingo M, Planas F, Casas T, et al. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. Int J Cardiol. 2007;120:338-343.
21. Bayés-Genís A, López L, Zapico E, Cotes C, Santaló M, Ordóñez-Llanos J, et al. NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. J Card Fail. 2005;11(5 Supl):S3-S8.